MBBS, FRCA, FRCP, FJFICM
Charlie is a Senior Intensive Care Specilaist at University Hospital Geelong, and the President of the College of Intensive Care Medicine
He undertook medical training at St Bartholomew’s hospital in London. After training as a physician he converted to anaesthesia and finally settled on becoming an intensive care specialist. After working in Hong Kong he came to Australia, initially working as Director of Intensive Care at the Repatriation Hospital in Melbourne. In 1991 he became Director of Intensive Care in Geelong. He has had extensive invovlement with the College of Intensive Care Medicine, serving as an Examiner, and an Executive Member since 2003. In 2008 he stepped down as Director of ICU at UHG to concentrate on his diverse medical interests.
Charlies careers include;
- Former President of the College of Intensive Care Medicine
- Regional clinical lead for the Respecting Patient Choices program
- Originator of the ‘MyValues’ approach to advance care planning
- Former Director ICU, Bawon Health
Charlie has published a number of papers and books on medicine and was featured on the ABC in the film ‘In the End’, and 'Insight'.
Respecting Patient Choices
Latest news:
-
Tuesday, June 28, 2022 - 12:15
JAMA NITRIC Trial: Among 1371 infants undergoing congenital heart surgery requiring CPB, delivery of nitric oxide into the CPB did not increase ventilator-free survival censored at 28 days. No benefit in secondary outcomes or subgroups was observed, including subgroup of children less than 6-weeks.
Tuesday, June 28, 2022 - 10:51JAMA Viewpoint: Surrogate decision-making is difficult. Respecting the authenticity and sovereignty of advance care directives,. Juggling these with the emotional burden of conflicting family morals during substituted judgement. Wendler expertly provides us the hierarchy of values for autonomy in treatment decision-making - non-intrusion, sovereignty, authenticity, best interest, moral standing - and urges us to consider them in our care.
Thursday, June 23, 2022 - 14:36NEJM LOVIT IV vitamin C in critically ill patients with sepsis requiring vasopressors associated increased risk of death or organ dysfunction at D28 vs placebo. Secondary outcomes including biomarkers identify no mechanism. Only RCT reporting benefit is CITRIS-ALI (lung injury), with no benefit septic shock (LOVIT, VITAMINS, ACTS, VICTAS). Ongoing COVID-19 and ARDS trials may further elucidate.
Thursday, June 23, 2022 - 13:01NEJM CLASSIC Trial: No difference 90-day mortality or serious adverse events among patients who received restricted fluid therapy vs standard therapy. The two groups had similar survival durations without life support and after hospital discharge at 90 days
Thursday, June 23, 2022 - 11:57JAMA PREPARE II Among critically ill adults undergoing tracheal intubation, administration of a fluid bolus did not significantly decrease the incidence of cardiovascular collapse